<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04064190</url>
  </required_header>
  <id_info>
    <org_study_id>MP-VAC-202</org_study_id>
    <nct_id>NCT04064190</nct_id>
  </id_info>
  <brief_title>Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition</brief_title>
  <official_title>A Phase 2 Study of TGF-β Inhibition (Vactosertib) With Anti-PD-L1 (Durvalumab) in Patients With Advanced or Recurrent Urothelial Carcinoma Failing to Achieve Response With Checkpoint Inhibition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedPacto, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MedPacto, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is Phase 2, open label, non randomized single arm study to determine whether the&#xD;
      administration of vactosertib with durvalumab will provide meaningful increases in the&#xD;
      Overall Response Rate (ORR) in patients with urothelial cancers that fail to achieve a&#xD;
      response with anti-PD-1/PD-L1 based regimens&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, open-label, non-randomized, two-cohort multi center study with a safety&#xD;
      run-in of 6 patients in Cohort 1. It is anticipated that a total of 48 patients will be&#xD;
      enrolled.&#xD;
&#xD;
      Durvalumab will be administered with the standard regimen of 1500 mg intravenously (IV) every&#xD;
      four weeks. Vactosertib will be administered at a dose of 300 mg PO BID for 5 days per week&#xD;
      All treatment will be administered up to two years and the trial is anticipated to be&#xD;
      completed over a period of 36 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase 2, open label, non randomized single arm study with two cohorts and a safety run-in for first six patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>12months</time_frame>
    <description>ORR by RECIST version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Response</measure>
    <time_frame>Overall study period up to 3years</time_frame>
    <description>TTR by RECIST version 1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Response</measure>
    <time_frame>Overall study period up to 3years</time_frame>
    <description>Best response (percent of tumor shrinkage) by RECIST version 1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Overall study period up to 3years</time_frame>
    <description>DoR by RECIST version 1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6-month/ 12-month</time_frame>
    <description>PFS by RECIST version 1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12month</time_frame>
    <description>OS by RECIST version 1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor-specific immune responses</measure>
    <time_frame>Overall study period up to 3years</time_frame>
    <description>tumor-specific immune responses within on-therapy biopsies measured by increased T cell infiltration and increased IFN-λ signature. and the correlation with outcome as measured by ORR, TTR, DoR, PFS and OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and tolerability]</measure>
    <time_frame>Overall study period up to 3years</time_frame>
    <description>To assess safety and tolerability of vactosertib administered concurrent with Durvalumab in patients with urothelial carcinoma failing checkpoint inhibition</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Urothelial Carcinoma Recurrent</condition>
  <condition>Advanced Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Vactosertib+Durvalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vactosertib will be administered in combination with standard dose of durvalumab every four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vactosertib(TEW-7197)/ Durvalumab</intervention_name>
    <description>Vactosertib (PO) in combination with Durvalumab (IV) every 4 weeks</description>
    <arm_group_label>Vactosertib+Durvalumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at&#xD;
             enrollment&#xD;
&#xD;
          2. Histologically or cytologically documented locally advanced/inoperable or metastatic&#xD;
             urothelial bladder carcinoma (UBC), including renal pelvis, ureters, urinary bladder,&#xD;
             and urethra.&#xD;
&#xD;
          3. Prior anti-PD-(L)1 treatment.&#xD;
&#xD;
          4. Measurable disease per RECIST 1.1 assessed by computed tomography (CT) scan or MRI.&#xD;
&#xD;
          5. Recurrent disease after any prior platinum-based chemotherapy regimen or ineligible&#xD;
             for platinum therapy.&#xD;
&#xD;
          6. Adequate organ and marrow function as defined&#xD;
&#xD;
          7. Must have a life expectancy of at least 12 weeks.&#xD;
&#xD;
          8. Body weight &gt; 30 kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allogeneic organ transplantation.&#xD;
&#xD;
          2. Active or prior documented autoimmune or inflammatory disorders&#xD;
&#xD;
          3. Uncontrolled intercurrent illness, including but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure .&#xD;
&#xD;
          4. History of another primary malignancy&#xD;
&#xD;
          5. History of leptomeningeal carcinomatosis.&#xD;
&#xD;
          6. History of active primary immunodeficiency.&#xD;
&#xD;
          7. Active infection including tuberculosis, hepatitis B (known positive HBV surface&#xD;
             antigen [HBsAg] result), hepatitis C, or human immunodeficiency virus .&#xD;
&#xD;
          8. Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy with the&#xD;
             exception of alopecia, vitiligo, and the laboratory values defined in the inclusion&#xD;
             criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Fong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sunjin Hwang, MD</last_name>
    <phone>+82 2 6938 0206</phone>
    <email>sunjin.hwang@medpacto.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Larry Fong, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Gurkamal Chatta, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

